Retrophin (RTRX) Given Media Sentiment Score of 0.14

Media coverage about Retrophin (NASDAQ:RTRX) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Retrophin earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.0445015705341 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of research firms have issued reports on RTRX. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 target price on shares of Retrophin in a report on Friday, October 6th. Finally, BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Retrophin has an average rating of “Buy” and an average price target of $36.00.

Shares of Retrophin (NASDAQ:RTRX) opened at $21.04 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83. Retrophin has a fifty-two week low of $15.55 and a fifty-two week high of $26.44.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The firm had revenue of $40.34 million during the quarter, compared to the consensus estimate of $40.51 million. During the same quarter in the prior year, the business posted ($0.09) EPS. Retrophin’s revenue was up 18.8% compared to the same quarter last year. sell-side analysts predict that Retrophin will post -1.25 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Retrophin (RTRX) Given Media Sentiment Score of 0.14” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/13/retrophin-rtrx-given-media-sentiment-score-of-0-14.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply